MARKET

AGIO

AGIO

Agios
NASDAQ

Real-time Quotes | Nasdaq Last Sale

46.51
-2.41
-4.93%
Opening 15:25 03/03 EST
OPEN
48.62
PREV CLOSE
48.92
HIGH
48.79
LOW
45.63
VOLUME
559.47K
TURNOVER
--
52 WEEK HIGH
58.93
52 WEEK LOW
27.77
MARKET CAP
3.24B
P/E (TTM)
-9.8122
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Agios cut to neutral at JPM citing valuation and lack of notable catalysts
The analysts at J.P. Morgan have downgraded Agios Pharmaceuticals ([[AGIO]] -0.0%) to neutral from overweight citing a lack of ‘game-changing’ catalysts in a year when the company turns its focus
Seekingalpha · 1d ago
BioCryst, Editas, Groupon, Sunrun, Twitter and More of Monday Afternoon’s Analyst Calls
247WallSt.com · 2d ago
Agios Pharmaceuticals Submits New Drug Application for Treatment of Rare and Aggressive Bile Duct Cancer
MT Newswires · 2d ago
BRIEF-Agios Submits Supplemental New Drug Application To FDA For Tibsovo (Ivosidenib Tablets) For Patients With Previously Treated Idh1-Mutant Cholangiocarcinoma
reuters.com · 2d ago
DJ Agios Seeks FDA Expanded OK for Tibsovo in IDH1-Mutant Cholangiocarcinoma >AGIO
Dow Jones · 2d ago
Agios submits TIBSOVO marketing application to FDA
Agios Pharmaceuticals (AGIO) announces that it has submitted a Supplemental New Drug Application ((sNDA)) to the U.S. FDA for TIBSOVO (ivosidenib tablets) as a potential treatment for patients with previously treated
Seekingalpha · 2d ago
Agios Submits Supplemental New Drug Application To FDA For TIBSOVO For Patients With Previously Treated IDH1-Mutant Cholangiocarcinoma
CAMBRIDGE, Mass., March 01, 2021 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and genetically defined diseases, today announced that it has
Benzinga · 2d ago
Agios Submits Supplemental New Drug Application to FDA for TIBSOVO® (ivosidenib tablets) for Patients with Previously Treated IDH1-Mutant Cholangiocarcinoma
CAMBRIDGE, Mass., March 01, 2021 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism to treat cancer and genetically defined diseases, today announced that it has submitted a Supplemental New Drug Ap...
GlobeNewswire · 2d ago
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of AGIO. Analyze the recent business situations of Agios through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 12 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average AGIO stock price target is 64.89 with a high estimate of 80.00 and a low estimate of 50.00.
EPS
Institutional Holdings
Institutions: 336
Institutional Holdings: 70.10M
% Owned: 100.72%
Shares Outstanding: 69.60M
TypeInstitutionsShares
Increased
63
5.04M
New
72
512.56K
Decreased
73
6.95M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-3.79%
Pharmaceuticals & Medical Research
-1.77%
Key Executives
Chairman/Director
David Schenkein
Chief Executive Officer/Director
Jacqualyn Fouse
Chief Financial Officer
Jonathan Biller
Senior Vice President/General Manager
Orlando Oliveira
Chief Scientific Officer
Bruce Car
Other
Christopher Bowden
Other
Darrin Miles
Director
David Scadden
Independent Director
Paul Clancy
Independent Director
Ian Clark
Independent Director
Kaye Foster
Independent Director
Maykin Ho
Independent Director
Kaye Foster-Cheek
Independent Director
John Maraganore
  • Dividends
  • Splits
  • Insider Activity
No Data
  • All
  • Financials
  • Insiders
More
About AGIO
Agios Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company's therapeutic areas of focus are cancer and rare genetic metabolic disorders, which are a group of over 600 rare genetic diseases caused by mutations, or defects, of single metabolic genes. The Company's cancer product candidates are enasidenib and ivosidenib (AG-120), which target mutated isocitrate dehydrogenase 2 (IDH2) and isocitrate dehydrogenase 1 (IDH1), respectively, and AG-881, which targets both mutated IDH1 and mutated IDH2. These mutations are found in a range of hematological malignancies and solid tumors. The lead product candidate in its rare genetic metabolic disorder (RGD), programs, AG-348, targets pyruvate kinase-R for the treatment of pyruvate kinase deficiency. Pyruvate kinase deficiency is a rare disorder that often results in severe hemolytic anemia due to inherited mutations in the pyruvate kinase enzyme within red blood cells.

Webull offers kinds of Agios Pharmaceuticals Inc stock information, including NASDAQ:AGIO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AGIO stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading AGIO stock methods without spending real money on the virtual paper trading platform.